Effects of sildenafil on maternal hemodynamics and fetal growth in normal rat pregnancy

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 298, Issue 2, 2010, Pages

  Sasser, Jennifer M ^a   Baylis, Chris ^a,b  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Phosphodiesterase 5; Sodium retention; Volume expansion

Indexed keywords

CREATININE; CYCLIC GMP; SILDENAFIL; SODIUM;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA; ARTERIAL PRESSURE; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MEGADOSE; FEMALE; FETOPLACENTAL UNIT; FETUS; FETUS GROWTH; FLUID INTAKE; FOOD INTAKE; KIDNEY TUBULE ABSORPTION; LOW DRUG DOSE; NONHUMAN; PLACENTA PERFUSION; PLASMA VOLUME; PREGNANCY; PRIORITY JOURNAL; RAT; SODIUM BALANCE; URINE VOLUME; WEIGHT GAIN;

ANIMALS; BLOOD PRESSURE; CREATININE; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; FEMALE; FETAL DEVELOPMENT; FETUS; HEMATOCRIT; HEMODYNAMICS; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PLASMA VOLUME; PREGNANCY; PREGNANCY, ANIMAL; PURINES; RATS; RATS, SPRAGUE-DAWLEY; REGIONAL BLOOD FLOW; SODIUM; SULFONES; VASODILATOR AGENTS;

EID: 75449091785     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00198.2009     Document Type: Article

References (21)

1. Abbott D, Comby P, Charuel C, Graepel P, Hanton G, Leblanc B, Lodola A, Longeart L, Paulus G, Peters C, Stadler J. Preclinical safety profile of sildenafil. Int J Impot Res 16: 498-504, 2004.
2. Burnett AL. Phosphodiesterase 5 mechanisms and therapeutic applications. Am J Cardiol 96: 29M-31M, 2005.
3. Conrad KP, Joffe GM, Kruszyna H, Kruszyna R, Rochelle LG, Smith RP, Chavez JE, Mosher MD. Identification of increased nitric oxide biosynthesis during pregnancy in rats. FASEB J 7: 566-571, 1993.
4. x diet. Am J Physiol Renal Physiol 277: F48-F57, 1999.
5. Corbin JD, Francis SH, Webb DJ. Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction. Urology 60: 4-11, 2002.
6. Downing JW, Ramasubramanian R, Johnson RF, Minzter BH, Paschall RL, Sundell HW, Engelhardt B, Lewis R. Hypothesis: selective phosphodiesterase-5 inhibition improves outcome in preeclampsia. Medical Hypotheses 63: 1057-1064, 2004.
7. George SK, Dipu MT, Mehra UR, Verma AK, Ramgaokar JS. Improved HPLC method for the simultaneous determination of allantoin,uric acid and creatinine in cattle urine. J Chromatogr B 832: 134-137, 2006.
8. Kass DA, Champion HC, Beavo JA. Phosphodiesterase Type 5: Expanding roles in cardiovascular regulation. Circ Res 101: 1084-1095, 2007.
9. Knight S, Snellen H, Humphreys M, Baylis C. Increased renal phosphodiesterase-5 activity mediates the blunted natriuretic response to ANP in the pregnant rat. Am J Physiol Renal Physiol 292: F655-F659, 2007.
10. Maharaj CH, O'Toole D, Lynch T, Carney J, Jarman J, Higgins BD, Morrison JJ, Laffey JG. Effects and mechanisms of action of sildenafil citrate in human chorionic arteries. Reprod Biol Endocrinol 7: 34, 2009.
11. Martin JA, Hamilton BE, Sutton PD, Ventura SJ, Menacker F, Kirmeyer S, Matthews TJ. Births: final data for 2006. National Vital Statistics Reports 57: 7, 2009.
12. Miller SL, Loose JM, Jenkin G, Wallace EM. The effects of sildenafil citrate (Viagra) on uterine blood flow and well being in the intrauterine growth-restricted fetus. Am J Obstet Gynecol 200: 102. e1-e7, 2009.
13. Ni XP, Safai M, Rishi R, Baylis C, Humphreys MH. Increased activity of cGMP-specific phosphodiesterase (PDE5) contributes to resistance to atrial natriuretic peptide natriuresis in the pregnant rat. J Am Soc Nephrol 15: 1254-1260, 2004.
14. Refuerzo JS, Sokol RJ, Aranda JV, Hallak M, Hotra JW, Kruger M, . Sorokin Y. Sildenafil citrate and fetal outcome in pregnant rats. Fetal Diagn Ther 21: 259-263, 2006.
15. Roberts JM, Pearson G, Cutler J, Lindheimer M. Summary of the NHLBI working group on research on hypertension during pregnancy. Hypertension 41: 437-445, 2003.
16. Samangaya RA, Mires G, Shennan A, Skillern L, Howe D, McLeod A, Baker PN. A randomised, double-blinded, placebo-controlled study of the phosphodiesterase type 5 inhibitor sildenafil for the treatment of preeclampsia. Hypertens Pregnancy 28: 369-382. 2009.
17. Stella CL, Sibai BM. Preeclampsia: diagnosis and management of the atypical presentation. J Matern Fetal Neonatal Med 19: 381-386, 2006.
18. Tsikas D, Wolf A, Frolich JC. Simplified HPLC method for urinary, and circulating creatinine. Clin Chem 50: 201-203, 2004.
19. Turgut NH, Temiz TK, Bagcivan I, Turgut B, Gulturk S, Karadas B. The effect of sildenafil on the altered thoracic aorta smooth muscle responses in rat pre-eclampsia model. Eur J Pharmacol 589(1-3): 180-187, 2008.
20. Villanueva-García D, Mota-Rojas D, Hernández- González R, Sánchez-Aparicio P, Alonso-Spilsbury M, Trujillo-Ortega ME, Necoechea RR, Nava-Ocampo AA. A systematic review of experimental and clinical studies of sildenafil citrate for intrauterine growth restriction and pre-term labour. J Obstet Gynaecol 27: 255-259, 2007.
21. Wareing M, Myers JE, O'Hara M, Baker PN. Sildenafil citrate (Viagra) enhances vasodilatation in fetal growth restriction. J Clin Endocrinol Metab 90: 2550-2555, 2005.